NHS National Pharmaceuticals Transition 2021_3

Tender description

NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633 Lot 1: Hospital Only Products – CESW region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products:LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition:LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 2: Hospital Only Products – LSNE region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: Hospital Only Products – NWLN region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 4: Oral (plus non-parenteral) products: All regions NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 6: Transition Products – LSNE region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 5: Transition Products – CESW region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Lot 7: Transition Products – NWLN region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months)